KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Current Investments (2020 - 2026)

AbCellera Biologics filings provide 7 years of Cash & Current Investments readings, the most recent being $102.1 million for Q1 2026.

  • Quarterly Cash & Current Investments fell 83.81% to $102.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $102.1 million through Mar 2026, down 83.81% year-over-year, with the annual reading at $558.8 million for FY2025, 14.11% down from the prior year.
  • Cash & Current Investments hit $102.1 million in Q1 2026 for AbCellera Biologics, down from $558.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $911.5 million in Q4 2022 and bottomed at $102.1 million in Q1 2026.
  • Average Cash & Current Investments over 5 years is $506.1 million, with a median of $558.8 million recorded in 2025.
  • The largest annual shift saw Cash & Current Investments soared 310.95% in 2024 before it crashed 83.81% in 2026.
  • AbCellera Biologics' Cash & Current Investments stood at $911.5 million in 2022, then crashed by 82.63% to $158.3 million in 2023, then soared by 310.95% to $650.6 million in 2024, then decreased by 14.11% to $558.8 million in 2025, then crashed by 81.74% to $102.1 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Cash & Current Investments are $102.1 million (Q1 2026), $558.8 million (Q4 2025), and $520.7 million (Q3 2025).